the safety of first-line (1L) nivolumab plus iplimumab (NIVO + IPI) therapy was similar to that of other approved combination therapies involving an immuno-oncology agent and chemotherapy. The retrospective, observational analysis, published in Future Oncology, sought to clarify the safety profile of 1L NIVO+ IPI because although the regimen has been declared as safe by the FDA, some patients still experience adverse events.